Business Context and Reporting Period
This Form 8-K, filed by Landec Corporation on May 5, 2010, reports events occurring on April 30, 2010. The filing details the completion of the acquisition of Lifecore Biomedical, Inc. ("Lifecore") and its subsidiary, Lifecore Biomedical, LLC ("LBL"), from Warburg Pincus Private Equity IX, L.P. The transaction represents a material definitive agreement and the completion of an asset acquisition.
Key Financial Metrics and Transaction Terms
- Acquisition Consideration: Initial cash payment of $40.0 million.
- Escrow Arrangement: $6.6 million of the purchase price was held in escrow (50% for 12 months, 50% for 24 months) to secure seller obligations.
- Debt Assumption: Landec permitted Lifecore to retain approximately $4.0 million of existing debt.
- Seller Distribution: The seller received a cash distribution of approximately $8.0 million from Lifecore on the closing date.
- Contingent Consideration: A potential earn-out of up to $10.0 million based on Lifecore achieving financial targets in calendar years 2011 and 2012.
- New Financing: LBL secured a $20.0 million senior secured term loan from Wells Fargo Bank with a five-year term.
- Interest Rate: The new loan accrues interest at a fixed rate of 4.24% via an interest rate swap.
- Guarantees: Landec and its subsidiaries guarantee all obligations of LBL under the new credit agreement and a related reimbursement agreement for a $4.2 million letter of credit.
Material Changes Versus Prior Period
This filing represents a significant structural change for Landec Corporation through the addition of Lifecore as a wholly-owned subsidiary. The company has incurred new direct financial obligations totaling $20.0 million in new debt and assumed existing debt of $4.0 million. Additionally, the company has created contingent liabilities via the $10.0 million earn-out provision. The filing does not provide comparative revenue, profit, or cash flow metrics for the prior period as this is a transaction report rather than a periodic financial statement.
Guidance, Outlook, Risks, and Unusual Items
Forward-Looking Statements: The filing includes standard cautionary language regarding forward-looking statements, noting that projections are based on current expectations and are not guarantees of future performance.
Risks and Contingencies:
- Debt Service: The company is now obligated to service the new $20.0 million loan and the retained $4.0 million debt.
- Collateral: The new debt is secured by a lien on all of LBL's personal property assets. The reimbursement agreement for the letter of credit is secured by a mortgage on LBL's building in Chaska, Minnesota.
- Earn-Out Risk: Future cash outflows of up to $10.0 million depend on Lifecore's performance in 2011 and 2012.
Unusual Items: The transaction involved a simultaneous distribution of $8.0 million to the seller and the assumption of specific debt structures, including a swap to fix interest rates.
Important Facts for Investor Verification
- Verify the specific financial targets required to trigger the $10.0 million earn-out payment.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for detailed representations, warranties, and indemnification terms.
- Monitor the upcoming filing of pro forma financial information, which is scheduled to be filed by amendment within 71 calendar days of the initial report.
- Confirm the impact of the $20.0 million new debt and $4.0 million assumed debt on Landec's overall leverage ratios and liquidity position.
- Assess the integration risks associated with combining Lifecore's operations with Landec's existing business.